Minerva Neurosciences (NERV) Common Equity (2013 - 2026)

Minerva Neurosciences has reported Common Equity for 14 years, with the latest figure at -$254.0 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 771.44% year-over-year to -$254.0 million; the trailing twelve-month figure through Mar 2026 stood at -$254.0 million (down 771.44% YoY), and the FY2025 full-year result was -$140.7 million, down 447.8% from the prior year.
• Common Equity for Q1 2026 stood at -$254.0 million, down from -$140.7 million in the prior quarter.
• The five-year high for Common Equity was -$736130.0 in Q1 2022, with the low at -$254.0 million in Q1 2026.
• Historically, Common Equity has averaged -$44.1 million across 5 years, with a median of -$26.6 million in 2023.
• Annual changes were most pronounced in 2023 — Common Equity sank 3515.96% — and 2025, when it grew 27.83%.
• Minerva Neurosciences' Common Equity stood at -$20.0 million in 2022, then plunged by 42.12% to -$28.5 million in 2023, then climbed by 9.71% to -$25.7 million in 2024, then plunged by 447.8% to -$140.7 million in 2025, then tumbled by 80.47% to -$254.0 million in 2026.
• The last three Common Equity figures came in at -$254.0 million (Q1 2026), -$140.7 million (Q4 2025), and -$34.6 million (Q3 2025), per Business Quant data.